Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; collaboration with Alexion Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases; a license agreement with City of Hope; and a licensing and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of medicines in the areas of cardio-metabolic disease, neurodegeneration, and pain. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-621-8097
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.28 million
Profitability
Miscellaneous
Employees44
OptionableOptionable
Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions
What is Dicerna Pharmaceuticals' stock symbol?
Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."
How were Dicerna Pharmaceuticals' earnings last quarter?
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) announced its quarterly earnings data on Wednesday, August, 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.26. The biopharmaceutical company earned $1.55 million during the quarter, compared to analysts' expectations of $1.79 million. Dicerna Pharmaceuticals had a negative return on equity of 63.24% and a negative net margin of 1,418.01%. View Dicerna Pharmaceuticals' Earnings History.
When is Dicerna Pharmaceuticals' next earnings date?
What price target have analysts set for DRNA?
9 analysts have issued twelve-month price objectives for Dicerna Pharmaceuticals' shares. Their forecasts range from $17.00 to $30.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $21.75 in the next twelve months. This suggests a possible upside of 90.1% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.
What is the consensus analysts' recommendation for Dicerna Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.
Has Dicerna Pharmaceuticals been receiving favorable news coverage?
Press coverage about DRNA stock has been trending positive recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near future.
Who are some of Dicerna Pharmaceuticals' key competitors?
Some companies that are related to Dicerna Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Akcea Therapeutics (AKCA), Arena Pharmaceuticals (ARNA), Endo International (ENDP), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Heron Therapeutics (HRTX), Insmed (INSM), Madrigal Pharmaceuticals (MDGL) and Portola Pharmaceuticals (PTLA).
Who are Dicerna Pharmaceuticals' key executives?
Dicerna Pharmaceuticals' management team includes the folowing people:
- Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 50)
- Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 54)
- Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 66)
- Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
- Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 72)
Who are Dicerna Pharmaceuticals' major shareholders?
Dicerna Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include RTW Investments LP (9.42%), BlackRock Inc. (6.90%), RA Capital Management LLC (3.92%), Emerald Advisers LLC (1.61%), Emerald Mutual Fund Advisers Trust (1.44%) and Northern Trust Corp (1.03%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Brian K Halak, Dennis Langer and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.
Which institutional investors are selling Dicerna Pharmaceuticals stock?
DRNA stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Two Sigma Advisers LP, Squarepoint Ops LLC, MetLife Investment Advisors LLC, Eversept Partners LP, New York State Common Retirement Fund and Emerald Mutual Fund Advisers Trust. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Brian K Halak, Dennis Langer and James B Weissman. View Insider Buying and Selling for Dicerna Pharmaceuticals.
Which institutional investors are buying Dicerna Pharmaceuticals stock?
DRNA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., RTW Investments LP, Emory University, Candriam Luxembourg S.C.A., Citigroup Inc., Fosun International Ltd, Geode Capital Management LLC and Artal Group S.A.. View Insider Buying and Selling for Dicerna Pharmaceuticals.
How do I buy shares of Dicerna Pharmaceuticals?
Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dicerna Pharmaceuticals' stock price today?
One share of DRNA stock can currently be purchased for approximately $11.44.
How big of a company is Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals has a market capitalization of $717.65 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.
What is Dicerna Pharmaceuticals' official website?
How can I contact Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]
MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
